Avammune Therapeutics
Bengaluru drug discovery company developing small-molecule immunotherapies that target innate immunity in cancer and autoimmune disease; lead candidate AVA-NP-695 is an ENPP1 inhibitor with preclinical activity in osteosarcoma, Ewing's sarcoma and triple-negative breast cancer, alongside an ADAR1-p150 program.
Headquarters
Bengaluru, India
Year Founded
2020
Founders
Arun B. Papaiah (CEO), Aditya Kulkarni (CSO), Srinivasan Namala
Country
India
Financial Information
Funding Stage
Series A
Recent Funding
$12M
Funding By
Capital 2B, Shastra VC, Kotak Life Sciences Fund I, IvyCap Ventures, 1Crowd
Core Technology
Small-molecule innate immune modulation (ENPP1 and ADAR1-p150 inhibition)
Product Type
Drug
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
Not disclosed
Academic / Hospital Tie-ups
Not disclosed
CRO/CDMO Partnerships
Not disclosed
Market & Differentiation
Innate-immunity targets aimed at cancers with high unmet need, including sarcoma